anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NSAIDs, including oxaprozin, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of OXAPROZIN CAPSULES at the first appearance of skin rash or any other sign of hypersensitivity. OXAPROZIN CAPSULES is contraindicated in patients with previous serious skin reactions to NSAIDs [see Contraindications (4)].
Those participants allocated to the D-med group will have the DOT intervention started after a 6 week "intervention-free" interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up.
PURPOSE:To easily prepare a high quality dehydrated article without lowering the quality of foods of medicines, by containing anhydrous lactitol to a water- containing substance to convert the same to a lactitol hydrate crystal. CONSTITUTION:Anhydrous lactitol is contained in a water-containing substance such as foods, medicines, cosmetics or stock materials thereof and changed to a lactitol hydrate crystal to perform dehydration. Anhydrous lactitol is substantially anhydrous one and develops strong dehydrating action when is converted to the lactitol hydrate crystal and the moisture thereof according to a Karl Fischer's method is pref. below 3w/w% or less and the pref. addition amount thereof is 0.0-500pts.wt. of 1pt. of the water-containing substance. This method can be especially advantageously adapted to the dehydration of organs, tissues or cells derived from an animal, a plant and a microorganism.
Status Epilepticus (SE), unresponsive to medical management, is associated with high morbidity and mortality. Surgical management is typically considered in these refractory cases. The best surgical approach for affected patients remains unclear; however, given the lack of controlled trials exploring the role of surgery. We performed a systematic review according to PRIMSA guidelines, including case reports and series describing surgical interventions for patients in SE. Cases (157 patients, median age 12.9 years) were followed for a median of 12 months. Patients were in SE for a median of 21 days before undergoing procedures including: focal resection (36.9%), functional hemispherectomy (21%), lobar resection (12.7%), vagus nerve stimulation (VNS) (12.7%), deep brain stimulation (DBS) (6.4%), multiple subpial transection (MST) (3.8%), responsive neurostimulation (RNS) (1.9%), and cortical stimulator placement (1.27%), with 24 patients undergoing multiple procedures. Multiple SE semiologies were identified. 47.8% of patients had focal seizures, and 65% of patients had focal structural abnormalities on MRI. SE persisted for 36.8 ± 47.7 days prior to surgical intervention. SE terminated following surgery in 81.5%, terminated with additional adjuncts in 10.2%, continued in 1.9%, and was not specified in 6.4% of patients. Long-term seizure outcomes were favorable, with the majority improved and 51% seizure-free. Eight patients passed away in follow-up, of which three were in SE. Seizures emerging from one hemisphere were both more likely to immediately terminate (OR 4.7) and lead to long-term seizure-free status (OR 3.9) compared to nonunilateral seizures. No other predictors, including seizure focality, SE duration, or choice of surgical procedure, were predictors of SE termination. Surgical treatment of SE can be effective in terminating SE and leading to sustained seizure freedom, with many different procedures showing efficacy if matched appropriately with SE semiology and etiology. PLAIN LANGUAGE SUMMARY: Patients with persistent seizures (Status Epilepticus) that do not stop following medications can be treated effectively with surgery. Here, we systematically review the entirety of existing literature on surgery for treating status epilepticus to better identify how and when surgery is used and what patients do after surgery.
VICTOZA was evaluated in a 26-week, double-blind, randomized, parallel group, placebo controlled multi-center trial (NCT01541215), in 134 pediatric patients with type 2 diabetes aged 10 years and older. Patients were randomized to VICTOZA once-daily or placebo once-daily in combination with metformin with or without basal insulin treatment. All patients were on a metformin dose of 1000 to 2000 mg prior to randomization. The basal insulin dose was decreased by 20% at randomization and VICTOZA was titrated weekly by 0.6 mg for 2 to 3 weeks based on tolerability and an average fasting plasma glucose goal of <110 mg/dL.

The mean age was 14.6 years: 29.9% were ages 10-14 years, and 70.1% were greater than 14 years of age. 38.1% were male, 64.9% were White, 13.4% were Asian, 11.9% were Black or African American; 29.1% were of Hispanic or Latino ethnicity. The mean BMI was 33.9 kg/m2 and the mean BMI SDS was 2.9. 18.7% of patients were using basal insulin at baseline. The mean duration of diabetes was 1.9 years and the mean HbA1c was 7.8%.

At week 26, treatment with VICTOZA was superior in reducing HbA1c from baseline versus placebo. The estimated treatment difference in HbA1c reduction from baseline between VICTOZA and placebo was   
-1.06% with a 95% confidence interval of [-1.65%; -0.46%] (see Table 12).

Table 12 Results at week 26 in a trial comparing VICTOZA in combination with metformin with or without basal insulin versus Placebo in combination with metformin with or without basal insulin in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus

a The change from baseline to end of treatment visit in HbA1c and FPG was analyzed using a pattern mixture model with multiple imputation. Missing observations (10.6% in the VICTOZA, 14.5% in the placebo) were imputed from the placebo arm based on multiple (x10,000) imputations. The data for week 26 was then analyzed with an ANCOVA model containing treatment, sex and age group as fixed effects and baseline value as covariate.

b Categories are derived from continuous measurements of HbA1c using a pattern mixture model with multiple imputation for missing observations. 

* p-value <0.001
Although the United States Food & Drug Administration (FDA) has provided guidance on the control of drug degradants for prescription drugs, there is less guidance on how to set degradant specifications for FDA OTC monograph drugs. Given that extensive impurity testing was not part of the safety paradigm in original OTC monographs, a weight of evidence (WOE) approach to qualify OTC degradants is proposed. This approach relies on in silico tools and read-across approaches alongside standard toxicity testing to determine safety. Using several drugs marketed under 21 CFR 341 as case studies, this research demonstrates the utility of a WOE approach across data-rich and data-poor degradants. Based on degradant levels ranging from 1 to 4% of the maximum daily doses of each case study drug and 10th percentile body weight data for each patient group, children were recognized as having the highest potential exposure relative to adults per body mass. Depending on data availability and relationship to the parent API, margins of safety (MOS) or exposure margins were calculated for each degradant. The findings supported safe use, and indicated that this contemporary WOE approach could be utilized to assess OTC degradants. This approach is valuable to establish specifications for degradants in OTCs.
Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
All patients with acute appendicitis who undergo appendectomies will be eligible to participate, and families will be consented prior to surgery. The explanation of the procedure will be done verbally by the surgeon as it is the standard care at the hospital. A parental anxiety assessment will be done before surgery with the Amsterdam Preoperative Anxiety and Information Scale (APAIS). In addition, an email from one of the primary caregivers will be collected, and the caregiver will receive an email with a link to the post-operative questionnaire 10 days post-discharge. At 14 days post-discharge, they will receive a reminder email again with the link to the questionnaire. All responses to the questionnaire are voluntary and anonymous.
Methods for making dental crowns, bridges, inlays, onlays, veneers, fillings, and other restorations are provided. The methods involve using a two-phase light curing (TPLC) material. Preferably, the TPLC material used to form the dental restoration comprises a blend of polymerizable compounds; photopolymerization systems (a) and (b), and particulate filler materials (a) and (b). In a first light-curing step, curing light having a wavelength of greater than 420 nm is used to activate system (a). In a second light-curing step, curing light having a wavelength of less than 420 nm is used to activate system (b). The two step light-curing method is efficient and allows the dentist to make restorations having high mechanical strength and pleasing aesthetics.
Inflammatory vasculopathy is critical in sickle cell disease (SCD)-associated organ damage. An imbalance between pro-inflammatory and pro-resolving mechanisms in response to different triggers such as hypoxia/reoxygenation or infections has been proposed to contribute to the progression of SCD. Administration of specialized pro-resolving lipid mediators may provide an effective therapeutic strategy to target inflammatory vasculopathy and to modulate inflammatory response. Epeleuton (15 hydroxy eicosapentaenoic acid ethyl ester) is a novel, orally administered, second-generation ω-3 fatty acid with a favorable clinical safety profile. In this study we show that epeleuton re-programs the lipidomic pattern of target organs for SCD towards a pro-resolving pattern. This protects against systemic and local inflammatory responses and improves red cell features, resulting in reduced hemolysis and sickling compared with that in vehicle-treated SCD mice. In addition, epeleuton prevents hypoxia/reoxygenation-induced activation of nuclear factor-κB with downregulation of the NLRP3 inflammasome in lung, kidney, and liver. This was associated with downregulation of markers of vascular activation in epeleuton-treated SCD mice when compared to vehicle-treated animals. Collectively our data support the potential therapeutic utility of epeleuton and provide the rationale for the design of clinical trials to evaluate the efficacy of epeleuton in patients with SCD.
Obesity, even in children, is generally accompanied by a state of chronic inflammation. To combat childhood obesity, clinicians and scientists recommend lifestyle interventions that include increased physical activity and exercise in an attempt to promote weight loss and, consequently, decrease comorbidities associated with excess adiposity. More importantly, it appears that the influence of regular exercise may offer children with obesity a multitude of health benefits, independent of weight loss. However, the intensity of exercise required to elicit significant health benefits is still unclear. Therefore, the aim of the present project is to study the influence of high intensity interval exercise (HIIE) on the existing inflammatory state found in obesity. Specifically, the proposed project will examine endothelial function and markers of inflammation, such as TNFa, IL-6, hsCRP, and adiponectin, in children with obesity before and after an exercise intervention. The data will then be used to determine if changes in these values differ in magnitude based on the intensity of exercise. Children with obesity will be randomized into either moderate exercise or HIIE groups, and attend sessions 3 times per week for 6 weeks. The moderate group will cycle continuously for 30 minutes at 65%-70% of maximal heart rate and the HIIE group will perform ten, 2-minute bouts at 90%-95% of maximal heart rate. Outcome measures of body composition, aerobic capacity, blood lipids, glucose metabolism, endothelial function, and inflammation will be measured pre- and post-intervention. Results may help in establishing exercise protocols not only for children with obesity, but also other inflammatory diseases such as diabetes, cancer, and arthritis.
Shortness of breath and syncope are common symptoms of right ventricular failure caused by pulmonary arterial hypertension (PAH), which is the result of blockage and increased pressure in the pulmonary arteries. There is a significant amount of evidence supporting the idea that inflammation and vascular calcification (VC) are important factors in PAH pathogenesis. Therefore, we aimed to investigate the features of the inflammatory process and gene expression involved in VC in monocrotaline (MCT)-induced PAH rats. MCT (60 mg/kg, i.p.) was used to induce PAH. Animals were given normal saline or rosmarinic acid (RA) (10, 15, and 30 mg/kg, gavage) for 21 days. An increase in right ventricular systolic pressure was evaluated as confirming PAH. To determine the level of inflammation in lung tissue, pulmonary edema and the total and differential white blood cell counts in the bronchoalveolar lavage fluid were measured. Also, the expression of NFκB, OPG, Runx2, and P-selectin genes was investigated to evaluate the level of VC in the heart. Our experiment showed that RA significantly decreased right ventricular hypertrophy, inflammatory factors, NFκB, Runx2, and P-selectin gene expression, pulmonary edema, total and differential white blood cell count, and increased OPG gene expression. Therefore, our research showed that RA protects against MCT-induced PAH by reducing inflammation and VC in rats.
This disclosure relates generally to method and system for spiking neural network based ECG classifier for wearable edge devices. Employing deep neural networks to extract the features from ECG signal have high computational intensity and large power consumption. The spiking neural network of the present disclosure obtains a training dataset comprising a plurality of ECG time-series data. The spiking neural network comprise a reservoir-based spiking neural network and a feed forward based spiking neural network. Each of the spiking neural network having a logistic regression-based ECG classifier are trained to classify one or more class labels. The peak-based spike encoder of each spiking neural network obtains a plurality of encoded spike trains from the plurality of ECG time-series. The peak-based spike encoder provides high performance for classifying one or more labels. Efficacy of the peak-based spike encoder for classification is experimentally evaluated with different datasets.
PCT No. PCT/GB94/02725 Sec. 371 Date Jul. 31, 1996 Sec. 102(e) Date Jul. 31, 1996 PCT Filed Dec. 13, 1994 PCT Pub. No. WO95/16672 PCT Pub. Date Jun. 22, 1995The invention relates to vitamin D amine and amide derivatives of general formula    <IMAGE>  (I)  where R represents a hydrogen atom, an aliphatic, cycloaliphatic or araliphatic group, or an acyl group comprising an aliphatic, cycloaliphatic, arylaliphatic or aryl group linked to the nitrogen atom by way of a carbonyl group; R1 and R2 are each selected from lower alkyl and cycloalkyl groups or together with the carbon atom to which they are attached form a lower cycloalkyl group; R3 represents a methyl group having  alpha - or  beta -configuration; Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and A= represents a cyclohexylidene moiety characteristic of the A-ring of a 1  alpha -hydroxylated vitamin D or analogue thereof. Active compounds of the invention exhibit cell modulating activity and in certain cases may also have an effect on calcium metabolism. The compounds of the invention may be prepared by isomerizing a 5,6-trans isomer of formula (I) to a corresponding 5,6-cis isomer; by hydroxylating a 1-unsubstituted-5,6-trans analogue of a compound of formula (I) to prepare a 5,6-trans isomer of formula (I); by reacting a compound containing a precursor for the desired 17-position side chain in one or more stages and with one or more reactants serving to form the desired side chain; or by reacting a compound of formula (I) to modify the substitution pattern about the A= group.
PURPOSE:A preventing and treating agent for nephritis containing sodium cromoglicate as an active constituent. CONSTITUTION:A preventing and treating agent for nephritis containing sodium cromoglicate, effective against bronchial asthma and allergic rhinits by spray inhalation administration and allergic conjunctivitis by eye crop administration and expressed by the formula and particularly useful for nephritis (IgA nephritis) involving immunoglobulin A. The above-mentioned compound inhibits the production of immunoglobulin, e.g. IgA, and formation of immune complex. As a result, IgA deposition on glomerular mesangium of the kidney is prevented and preventing and treating effect on IgA nephritis is exhibited. The dose of the above-mentioned compound is normally 10-40mg/kg a day depending on the symptom of the patient.
<P>PROBLEM TO BE SOLVED: To provide a hair growth tonic exhibiting an excellent hair growth effect.  <P>SOLUTION: This hair growth tonic containing the aqueous solution of a water-soluble dimer iron salt (ferrous ferric chloride)is characterized in that the aqueous solution contains magnesium ion and calcium ion. The hair growth tonic is characterized by further containing the extracts of Lycium chinense and Acanthopanax senticosus. The hair growth tonic has a hair growth effect for promoting the proliferation and differentiation of keratinocyte, melanoblast and melanocyte which participate in the growth of hair. The aqueous solution of the water-soluble dimer iron salt is also used for drinking water, and therefore does not give an undesirable irritation to scalps.  <P>COPYRIGHT: (C)2008,JPO&INPIT
BACKGROUND: Pregnant women are at an increased risk of severe COVID-19 and adverse pregnancy outcomes; data on maternal long-term outcome is scarce. We analyzed long-term follow-ups on women who experienced a SARS-CoV-2 infection during pregnancy to evaluate post-COVID symptoms, particularly fatigue, and their association with quality of life (QoL).
METHODS: 773 women who enrolled in the CRONOS registry between April 2020 and August 2021 were contacted for follow-up from December 2022 to April 2023. Data was gathered through a web-based questionnaire. Subsequently, study coordinators matched the follow-up data with the existing CRONOS data.
RESULTS: 110/773 (14%) women provided data. 20.9% experienced only acute symptoms during their SARS-CoV-2 infection in pregnancy, while 2.7% women experienced symptoms lasting longer than 4 weeks (long COVID). Symptoms lasting longer than 12 weeks (post-COVID) were reported by 63.6% women and occurred more often after severe COVID-19. Fatigue was the most frequently reported symptom (88%), with 55% of women still experiencing it more than one year after initial infection. 76% of women rated their QoL as "good" or "very good". Women experiencing post-COVID reported a significantly lower QoL.
CONCLUSION: This is the first German long-term data on women after SARS-CoV-2 infection during pregnancy, showing a high rate of post-COVID, a persistence of fatigue, and the impact on QoL. Continuous monitoring of pregnant women with COVID-19 is needed to develop comprehensive management strategies.
In the current study, thirty bacterial strains isolated from the rhizosphere of Clerodendrum infortunatum L. were evaluated for the properties related to the plant growth promotion and disease resistance. Here, all the selected strains were screened for its antagonistic effect towards the phytopathogen Sclerotium rolfsii and also for the production of bioactive compounds known to promote the plant growth. Among these isolates, CiRb1 and CiRb16 were observed to have a broad range of plant beneficial features and were identified as Bacillus licheniformis and Bacillus velezensis respectively. Both the isolates were also demonstrated to produce the volatile organic compounds (VOCs) responsible for the growth enhancement in Brassica nigra (L.) and growth inhibition of S. rolfsii. Talc based formulations made out of both B. licheniformis and B. velezensis were further demonstrated to augment the plant growth and protection against S. rolfsii in Vigna unguiculata (L.) Walp. By the GC-MS based analysis, undecane could also be detected in the methanolic extracts prepared from both B. licheniformis and B. velezensis. Here, the selected rhizobacterial isolates were found to promote the plant growth and disease resistance through both direct and VOC mediated mechanisms. The results of the study hence reveal both B. licheniformis and B. velezensis have the potential in field application to promote the growth and control of plant diseases.
PURPOSE:To provide the subject inhibiting substance inhibiting the activities of alpha-amylase and lipase and effectively inhibiting obesity and hyperglycemia as a dietary food by filtering the extraction solution of a sea alga and subsequently purifying the filtrate. CONSTITUTION:A brown alga (e.g. Undaria pinnatifida, sea tangle), a green alga (e.g. Ulva pertusa, Enteromorpha) or a red alga (e.g. Gracilaria, Gelidium subcostatum) is hot-extracted with a solvent, preferably water or an alcohol, and subsequently filtered. The filtrate is purified to provide the objective inhibiting substance.
A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection.